Get our comprehensive guide to direct listings, an increasingly common alternative to a traditional IPO. Download Now

Westicke Partners


Westwicke Blog

The Westwicke Blog is designed to deliver information and insights into the ever-changing world of healthcare communications.

10 Disclosure Guidelines for Clinical Trial Data and Milestones

Posted on October 21st, 2020. Posted by

As life science and medical device companies seek regulatory approval for their products, they will likely encounter difficult disclosure decisions around clinical and regulatory events. Clinical trial data and milestones can present great opportunities as well as significant challenges.

If done right, these milestones are a great way to raise visibility within the investment, clinical, and scientific communities. If done wrong, the consequences may be severe.

The checklist below outlines 10 disclosure guidelines that will allow you to control the message within the investment and medical communities, maximize shareholder value, and attract new investors and strategic partners.


Clinical Trials Disclosure


Victoria Meissner

Victoria Meissner, M.D., is a Vice President on Westwicke’s life sciences team. She has extensive experience in investor relations, capital raising, crisis communications, regulatory approval, and corporate strategy. She has an M.D. from the Medical University of Vienna and Ph.D. in microbiology and immunology from the University of Illinois at Chicago.

View full bio   |   Other posts by Victoria Meissner, M.D.

Thinking of taking your company public?

Our comprehensive eBook, Westwicke Insider’s Guide to Going Public, takes you all the way through the process, from a year before your IPO to a year after.

Our Locations